在药物开发过程中代表来自不同背景的人类是推进健康平等的关键，虽然临床试验设计近年来取得了更大的包容性进展，但在临床前药物开发方面仍然存在困难。其中一个包容性的障碍是当前缺乏强健、已建立的体外模型系统，能够同时捕捉人类组织的复杂性和代表病人多样性。在这里，提出使用原代人类肠器官模型作为推进包容性临床前研究的机制。这种体外模型系统不仅重新演绎了组织功能和疾病状态，还保留了捐献者的基因身份和表观基因组签名。因此，肠器官是捕捉人类多样性的理想体外原型。在这一观点中，作者呼吁整个行业努力利用肠器官作为起点，积极有意识地将多样性纳入临床前药物计划中。©2023 Genentech，Inc.由Wiley-VCH GmbH出版的Advanced Biology。

Representation of humans from diverse backgrounds in the drug development process is key to advancing health equity, and while clinical trial design has recently made strides toward greater inclusivity, preclinical drug development has struggled to make those same gains. One barrier to inclusion is the current lack of robust and established in vitro model systems that simultaneously capture the complexity of human tissues while representing patient diversity. Here, the use of primary human intestinal organoids as a mechanism to advance inclusive preclinical research is proposed. This in vitro model system not only recapitulates tissue functions and disease states, but also retains the genetic identity and epigenetic signatures of the donors from which they are derived. Thus, intestinal organoids are an ideal in vitro prototype for capturing human diversity. In this perspective, the authors call for an industry-wide effort to leverage intestinal organoids as a starting point to actively and intentionally incorporate diversity into preclinical drug programs.© 2023 Genentech, Inc. Advanced Biology published by Wiley-VCH GmbH.